• NICE recommends Novartis’ wet AMD drug Beovu pharmatimes
    December 16, 2020
    The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet age-related degeneration (AMD) patients.
PharmaSources Customer Service